250 related articles for article (PubMed ID: 32009296)
21. The role of incretin-based therapies in the management of type 2 diabetes.
Bandyopadhyay P
Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
[TBL] [Abstract][Full Text] [Related]
22. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
23. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
24. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
25. Incretin pharmacology: a review of the incretin effect and current incretin-based therapies.
Neumiller JJ
Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):276-88. PubMed ID: 22827291
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Mannucci E; Monami M
Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
[TBL] [Abstract][Full Text] [Related]
27. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.
Kawanami D; Matoba K; Sango K; Utsunomiya K
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483245
[TBL] [Abstract][Full Text] [Related]
28. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
29. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.
Scheen AJ
Diabetes Res Clin Pract; 2017 May; 127():224-237. PubMed ID: 28402902
[TBL] [Abstract][Full Text] [Related]
31. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon CF
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
[TBL] [Abstract][Full Text] [Related]
32. Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
van Baar MJB; van Raalte DH
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):103-111. PubMed ID: 31714285
[TBL] [Abstract][Full Text] [Related]
33. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
34. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
35. Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes.
Farngren J; Ahrén B
Metabolism; 2019 Oct; 99():25-31. PubMed ID: 31279738
[TBL] [Abstract][Full Text] [Related]
36. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
37. Incretin based therapy and pancreatic cancer: Realising the reality.
Suryadevara V; Roy A; Sahoo J; Kamalanathan S; Naik D; Mohan P; Kalayarasan R
World J Gastroenterol; 2022 Jul; 28(25):2881-2889. PubMed ID: 35978867
[TBL] [Abstract][Full Text] [Related]
38. Incretin-based therapies and renin-angiotensin system: Looking for new therapeutic potentials in the diabetic milieu.
Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
Life Sci; 2020 Sep; 256():117916. PubMed ID: 32534034
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
40. Incretin-based therapies in 2021 - Current status and perspectives for the future.
Rizzo M; Nauck MA; Mantzoros CS
Metabolism; 2021 Sep; 122():154843. PubMed ID: 34333000
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
